The Effect of Bisoprolol on Heart Failure Preserved Ejection Fraction / Hfpef Patient’s Quality Of Life

Ayu Asri Devi Adityawati,Mohammad Saifur Rohman,Anna Fuji Rahimah,Setyasih Anjarwani,Djanggan Sargowo

doi:10.21776/ub.hsj.2021.002.04.6

Abstract

Background: Global Public Health Burden of Heart Failure reported the growing prevalence of heart failure which is 64.3 million affected in 2020 worldwide with half of the case classified as Heart Failure Preserved Ejection Fraction (HFpEF). It is well known that someone who has been diagnosed with heart failure will have a poorer 􏰼􏰞􏰏􏰦􏰝􏰊􏰗 􏰓􏰒 􏰦􏰝􏰒􏰋􏰷􏰽􏰓􏰬􏰣 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑 􏰝􏰌 􏰏 􏰜􏰋􏰏􏰑􏰊 􏰑􏰏􏰊􏰋 􏰦􏰓􏰎􏰋􏰑􏰝􏰚􏰟 􏰏􏰟􏰋􏰚􏰊 􏰎􏰝􏰊􏰜 􏰏 􏰐􏰓􏰊􏰋􏰚􏰩􏰗 􏰊􏰓 􏰝􏰔􏰐􏰑􏰓􏰻􏰋 􏰊􏰜􏰋 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏱀􏰌 􏰩􏰦􏰝􏰚􏰝􏰩􏰏􏰦 outcomes, one of them is QoL. Objective􏱁 􏰥􏰜􏰝􏰌 􏰌􏰊􏰞􏰕􏰗 􏰏􏰝􏰔􏰋􏰕 􏰊􏰓 􏰓􏰖􏰌􏰋􏰑􏰻􏰋 􏰏􏰚􏰕 􏰋􏰻􏰏􏰦􏰞􏰏􏰊􏰋 􏰊􏰜􏰋 􏰋􏰒􏰒􏰋􏰩􏰊 􏰓􏰒 􏰖􏰝􏰌􏰓􏰐􏰑􏰓􏰦􏰓􏰦􏰳 􏰏 􏰊􏰗􏰐􏰋 􏰓􏰒 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑􏰳 􏰝􏰚 􏰊􏰜􏰋 􏰝􏰔􏰐􏰑􏰓􏰻􏰋- 􏰔􏰋􏰚􏰊 􏰓􏰒 􏱂􏱃􏰐􏰺􏱃 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏱀􏰌 􏰽􏰓􏰬􏰣 Method: This study is a retrospective cohort following HFpEF patients who received bisoprolol and HFpEF patients who did not receive bisoprolol. The study participants were selected using purposive sampling method. Result: Our study found that from all HFpEF patients who received bisoprolol 102 patients had a good QoL and 2 patients had a poor QoL (p=0.000) according to Minnesota Living With Heart Failure Questionnaire (MLHFQ). The median physical score in the patient who did not receive bisoprolol was 10 while the median score of the 􏰐􏰏􏰊􏰝􏰋􏰚􏰊 􏰎􏰜􏰓 􏰑􏰋􏰩􏰋􏰝􏰻􏰋􏰕 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑 􏰎􏰏􏰌 􏰲 􏰪􏰐􏰡􏰢􏰣􏰢􏰢􏰢􏰮􏰣 􏰥􏰜􏰋 􏰔􏰋􏰏􏰚 􏰋􏰔􏰓􏰊􏰝􏰓􏰚􏰏􏰦 􏰌􏰩􏰓􏰑􏰋 􏰒􏰓􏰑 􏰊􏰜􏰋 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏰌 􏰎􏰜􏰓 􏰕􏰝􏰕 􏰚􏰓􏰊 􏰑􏰋􏰩􏰋􏰝􏰻􏰋 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑 􏰎􏰏􏰌 􏰸 􏰎􏰜􏰝􏰦􏰋 􏰊􏰜􏰋 􏰔􏰋􏰏􏰚 􏰌􏰩􏰓􏰑􏰋 􏰓􏰒 􏰊􏰜􏰋 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏰌 􏰎􏰜􏰓 􏰑􏰋􏰩􏰋􏰝􏰻􏰋􏰕 􏰾􏰘􏰖􏰦􏰓􏰩􏰿􏰋􏰑 􏰎􏰏􏰌 􏱄 􏰪􏰐􏰡􏰢􏰣􏰢􏰢􏰢􏰮􏰣 Conclusion􏱁 􏰛􏰋 􏰩􏰓􏰚􏰩􏰦􏰞􏰕􏰋 􏰊􏰜􏰏􏰊 􏰊􏰜􏰋 􏰞􏰌􏰋 􏰓􏰒 􏰖􏰝􏰌􏰓􏰐􏰑􏰓􏰦􏰓􏰦 􏰩􏰓􏰞􏰦􏰕 􏰝􏰔􏰐􏰑􏰓􏰻􏰋 􏰊􏰜􏰋 􏱂􏱃􏰐􏰺􏱃 􏰐􏰏􏰊􏰝􏰋􏰚􏰊􏱀􏰌 􏰽􏰓􏰬 􏰋􏰻􏰏􏰦􏰞􏰏􏰊􏰋􏰕 􏰖􏰗 􏰊􏰓􏰊􏰏􏰦 score, physical score, and emotional score.

Highlights

Global Public Health Burden of Heart Failure reported that there was an increasing prevalence of heart failure from 26 million people affected in 2017 to 64.3 million people worldwide in 2020 with half of the case classified as heart failure preserved ejection fraction/HFpEF1
Our study followed 217 patients with 22 patients categorized as poor QoL and 195 patients categorized as good QoL (Table 1)
We found that 102 patients who received bisoprolol had a good QoL 2 other patients who received bisoprolol had a poor QoL

Summary

Introduction

Global Public Health Burden of Heart Failure reported that there was an increasing prevalence of heart failure from 26 million people affected in 2017 to 64.3 million people worldwide in 2020 with half of the case classified as heart failure preserved ejection fraction/HFpEF1. Global Public Health Burden of Heart Failure reported the growing prevalence of heart failure which is 64.3 million affected in 2020 worldwide with half of the case classified as Heart Failure Preserved Ejection Fraction (HFpEF). Objective: This study aimed to observe and evaluate the effect of bisoprolol, a type of β-blocker, in the improvement of HFpEF patient’s QoL. Conclusion: We conclude that the use of bisoprolol could improve the HFpEF patient’s QoL evaluated by total score, physical score, and emotional score

Objectives

Methods

Results

Conclusion